secwatch.observer — SEC 8-K summary
======================================

Issuer:     Replimune Group, Inc. (REPL)
CIK:        0001737953
Form:       8-K
Filed at:   2025-09-04T23:59:59+00:00
Accession:  0001104659-25-087464
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 5.07, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Replimune schedules Type A meeting with FDA to discuss RP1 CRL; program viability at risk
--------------------------------------------------------------------------------

- FDA Type A meeting scheduled to discuss CRL for RP1 BLA in advanced melanoma; briefing submitted with additional analysis.
- CEO states without accelerated approval, RP1 program in advanced melanoma, including phase 3 confirmatory trial, will not be viable.
- Stockholders voted against amending 2018 Omnibus Incentive Compensation Plan (26.97M for, 35.49M against).
- All director nominees elected; PwC ratification and say-on-pay proposals approved by stockholders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737953/000110465925087464/0001104659-25-087464-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737953/000110465925087464/tm2525185d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-087464

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer